Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

OCL468522 (corrected).pdf (450.61 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2017-01-01

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227589

The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1159/000468522

Resum

To analyze the role of audiometry in considering change to a less ototoxic treatment in head and neck cancer (HNC) patients.Consecutive patients prescribed high-dose cisplatin (100 mg/m2) between January 2013 and February 2015 were enrolled. Audiometry was performed at baseline and before cisplatin. Change to a less ototoxic agent or reduced cisplatin dose was considered with audiometric decreases >25 dB.A total of 103 patients were included; the median age of the patients was 59 years (range 18-75). Cisplatin was intended curative (58%), adjuvant (32%), or palliative (10%). Forty-two participants (41%) did not commence high-dose cisplatin because of baseline audiometric alterations. Of 61 patients treated with high-dose cisplatin, 40 (66%) showed marked ototoxicity at the end of treatment. The mean hearing loss between initial and final audiometries showed a hearing loss at 4 and 8 kHz in both ears (p = 0.002). Thirteen patients switched to carboplatin and 15 to a lower dose of cisplatin. The outcome was not significantly altered when cisplatin was replaced with carboplatin or cetuximab.Audiometric alterations are common in HNC with high-dose cisplatin, and switching to a less ototoxic regimen does not adversely affect outcome. Audiometric examination could help to prevent hearing loss in this population.© 2017 S. Karger AG, Basel.

Matèries

Matèries (anglès)

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

GRAU DE CASTRO, Juan Jose, et al. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer. Oncology. 2017. Vol. 93, num. 2, pags. 75-82. ISSN 1423-0232. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/227589

Exportar metadades

JSON - METS

Compartir registre